research use only
Cat.No.S8245
| Related Targets | HDAC PARP ATM/ATR DNA-PK WRN DNA/RNA Synthesis Topoisomerase PPAR Casein Kinase eIF |
|---|---|
| Other Sirtuin Inhibitors | SRT1720 HCl Selisistat (EX-527) Sirtinol Fisetin 3-TYP AGK2 SRT2104 (GSK2245840) OSS_128167 SirReal2 SRT2183 |
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| BxPC3 | Growth inhibition assay | 72 hrs | Growth inhibition of human BxPC3 cells after 72 hrs by CellTiter-Blue assay, GI50=13.3μM | 30986062 | ||
| MDA-MB-468 | Growth inhibition assay | 72 hrs | Growth inhibition of human MDA-MB-468 cells after 72 hrs by CellTiter-Blue assay, GI50=15.7μM | 30986062 | ||
| NCI-H23 | Growth inhibition assay | 72 hrs | Growth inhibition of human NCI-H23 cells after 72 hrs by CellTiter-Blue assay, GI50=16.4μM | 30986062 | ||
| HCT116 | Function assay | 5 days | Inhibition of anchorage-independent cell growth in human HCT116 cells assessed as reduction in colony formation incubated for 5 days followed by compound re-addition and measured after 9 to 11 days by nitro blue tetrazolium chloride-based soft agar colony, GI50=16.7μM | 30986062 | ||
| A549 | Growth inhibition assay | 72 hrs | Growth inhibition of human A549 cells after 72 hrs by CellTiter-Blue assay, GI50=17.3μM | 30986062 | ||
| SW948 | Growth inhibition assay | 72 hrs | Growth inhibition of human SW948 cells after 72 hrs by CellTiter-Blue assay, GI50=19.2μM | 30986062 | ||
| MCF7 | Growth inhibition assay | 72 hrs | Growth inhibition of human MCF7 cells after 72 hrs by CellTiter-Blue assay, GI50=37μM | 30986062 | ||
| MDA-MB-231 | Growth inhibition assay | 72 hrs | Growth inhibition of human MDA-MB-231 cells after 72 hrs by CellTiter-Blue assay, GI50=42.8μM | 30986062 | ||
| HeLa | Cytotoxicity assay | 50 uM | 72 hrs | Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 50 uM measured after 72 hrs by CCK8 assay | 31117516 | |
| MCF7 | Growth inhibition assay | 15 uM | 72 hrs | Growth inhibition of human MCF7 cells at 15 uM measured after 72 hrs by AlamarBlue assay | 31144814 | |
| Neuro2a | Function assay | 0.2 to 2 uM | 24 hrs | Induction of neurite outgrowth in mouse Neuro2a cells at 0.2 to 2 uM measured after 24 hrs by microscopic analysis | 31144814 | |
| HCT116 | Function assay | 25 uM | 6 hrs | Inhibition of SIRT2 in human HCT116 cells assessed as increase in alpha-tubulin acetylation at 25 uM incubated for 6 hrs by DAPI staining-based laser scanning confocal microscopic analysis | 30986062 | |
| HCT116 | Function assay | 50 uM | 6 hrs | Inhibition of SIRT2 in human HCT116 cells assessed as increase in alpha-tubulin acetylation at 50 uM incubated for 6 hrs by DAPI staining-based laser scanning confocal microscopic analysis | 30986062 | |
| Click to View More Cell Line Experimental Data | ||||||
|
In vitro |
DMSO
: 100 mg/mL
(171.86 mM)
Ethanol : 100 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 581.85 | Formula | C34H51N3O3S |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1429749-41-6 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | TM | Smiles | CCCCCCCCCCCCCC(=S)NCCCCC(C(=O)NC1=CC=CC=C1)NC(=O)OCC2=CC=CC=C2 | ||
| Targets/IC50/Ki |
SIRT2
(Cell-free assay) 28 nM
|
|---|---|
| In vitro |
Thiomyristoyl(TM) is a highly selective SIRT2 inhibitor. It cannot efficiently inhibit SIRT3, SIRT5, SIRT6, or SIRT7. In vitro, it shows great inhibition of cell viability and its cytotoxicity is relatively selective toward cancer cells. TM decreases c-Myc oncoprotein level in cancer cells, the ability of TM to decrease c-Myc abundance in different cell lines correlates with the sensitivity of the cell lines to TM.
|
| In vivo |
The anticancer effect of TM correlates with its ability to decrease c-Myc level. TM has limited effects on non-cancerous cells and tumor-free mice.
|
References |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06147232 | Not yet recruiting | Nephropathy|Diabetic Nephropathies|Diabetes Mellitus Type 1|Albuminuria|Diabetic Complications Renal|Diabetic Complications Cardiovascular|Hypoxia |
Steno Diabetes Center Copenhagen|Juvenile Diabetes Research Foundation|King''s College London|Glostrup University Hospital Copenhagen |
August 2024 | Phase 4 |
| NCT06384157 | Not yet recruiting | Opioid Use Disorder |
Indivior Inc. |
May 2024 | Phase 2 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.